Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
KEYNOTE-407: Pembrolizumab + Chemotherapy in Metastatic Squamous NSCLC
NCT02775435Phase 3Completed
- Sponsor
- Merck & Co.
- Start
- Jun 2016
- Primary completion
- Apr 2018
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes
01
Overview
A Phase 3 trial of pembrolizumab in squamous cell carcinoma of the lung (SCCL), sponsored by Merck & Co.. Started Jun 2016; status: completed.
02
Drugs
03
Conditions
squamous cell carcinoma of the lung (SCCL)
Beyond the preview
Go deeper on NCT02775435.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02775435.